{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:42:55Z","timestamp":1791020575382,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>Methods: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, double-blind, to telcagepant 140\u2009mg, telcagepant 280\u2009mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140\u2009mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as \u22653 successes, and lack of consistent efficacy was defined as \u22652 failures, in treatment response. A total of 1677 patients treated \u22651 attack and 1263 treated all four attacks.<\/jats:p>\n                  <jats:p>Results: Based on Attack 1 data, telcagepant 140\u2009mg and 280\u2009mg were significantly ( p\u2009&lt;\u2009.001) more effective than placebo for 2-hour pain freedom, 2-hour pain relief, 2-hour absence of migraine-associated symptoms (phonophobia, photophobia, nausea), and 2\u201324 hours sustained pain freedom. The percentage of patients with 2-hour pain freedom consistency and 2-hour pain relief consistency was significantly ( p\u2009&lt;\u2009.001) higher for both telcagepant treatment sequences versus control. Adverse events within 48 hours for telcagepant with an incidence \u22652% and twice that of placebo were somnolence (placebo\u2009=\u20092.3%, 140\u2009mg\u2009=\u20095.9%, 280\u2009mg\u2009=\u20095.7%) and vomiting (placebo\u2009=\u20091.4%, 140\u2009mg\u2009=\u20091.0%, 280\u2009mg\u2009=\u20092.9%).<\/jats:p>\n                  <jats:p>Conclusion: Telcagepant 140\u2009mg and 280\u2009mg were effective for treatment of a migraine attack and were more consistently effective than control for intermittent treatment of up to four migraine attacks. Telcagepant was generally well tolerated. (Clinicaltrials.gov; NCT00483704)<\/jats:p>","DOI":"10.1177\/0333102410370878","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T20:58:42Z","timestamp":1276030722000},"page":"1443-1457","source":"Crossref","is-referenced-by-count":68,"title":["Randomized, controlled trial of telcagepant over four migraine attacks"],"prefix":"10.1177","volume":"30","author":[{"given":"Andrew P","family":"Ho","sequence":"first","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl GH","family":"Dahl\u00f6f","sequence":"additional","affiliation":[{"name":"Gothenburg Migraine Clinic, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Silberstein","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel R","family":"Saper","sequence":"additional","affiliation":[{"name":"Michigan Head Pain and Neurological Institute, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[{"name":"Danish Headache Center and Glostrup Hospital, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T","family":"Kost","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Froman","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Leibensperger","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Lines","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony W","family":"Ho","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"bibr1-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"bibr2-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"bibr3-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.7.3.377"},{"key":"bibr4-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.07.035"},{"key":"bibr5-0333102410370878","doi-asserted-by":"publisher","DOI":"10.2217\/fnl.09.14"},{"key":"bibr6-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"bibr7-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000286940.29755.61"},{"key":"bibr8-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61626-8"},{"key":"bibr9-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b87942"},{"key":"bibr10-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00830.x"},{"key":"bibr11-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"bibr12-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00117.x"},{"key":"bibr13-0333102410370878","unstructured":"European Medicines Agency. Clinical Investigation of Medicinal Products for Treatment of Migraine. http:\/\/www.emea.europa.eu\/htms\/ human\/humanguidelines\/efficacy.htm. (Accessed 15 December 2009.)."},{"issue":"1","key":"bibr14-0333102410370878","first-page":"9","volume":"24","author":"International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"bibr15-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1995.hed3506330.x"},{"key":"bibr16-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"bibr17-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/63.3.655"},{"key":"bibr18-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.65.12_suppl_4.S50"},{"key":"bibr19-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.10.1511"},{"key":"bibr20-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.773"},{"key":"bibr21-0333102410370878","unstructured":"Merck & Co., Inc. Merck Announces First-Quarter 2009 Financial Results. Company Press Release, 21 April 2009. Available at: http:\/\/www.merck.com\/newsroom\/press_releases\/financial\/2009_0421.html (Last accessed 5 May 2010)."},{"key":"bibr22-0333102410370878","doi-asserted-by":"publisher","DOI":"10.1038\/313054a0"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102410370878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0333102410370878","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0333102410370878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:44:14Z","timestamp":1777387454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0333102410370878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1177\/0333102410370878"],"URL":"https:\/\/doi.org\/10.1177\/0333102410370878","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}